For example, the Checkmate-227 and Checkmate-568 studies demonstrated that TMB ≥ 10 muts/Mb could predict clinical benefits of nivolumab plus ipilimumab in patients with NSCLC, regardless of PD-L1 expression (15, 16). Here, CD274 is linked to non-small cell lung carcinoma.